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OBJECTIVE—Recent studies in European populations have
reported a reciprocal association of glucokinase regulatory pro-
tein (GCKR) gene with triglyceride versus fasting plasma glucose
(FPG) levels and type 2 diabetes risk. GCKR is a rate-limiting
factor of glucokinase (GCK), which functions as a key glycolytic
enzyme for maintaining glucose homeostasis. We examined the
associations of two common genetic polymorphisms of GCKR
and GCK with metabolic traits in healthy Chinese adults and
adolescents.
RESEARCH DESIGN AND METHODS—Two single nucleo-
tide polymorphisms (SNPs), rs780094 at GCKR and rs1799884 at
GCK, were genotyped in 600 healthy adults and 986 healthy
adolescents. The associations of these SNPs with metabolic traits
were assessed by linear regression adjusted for age, sex, and/or
BMI. We also tested for the epistasis between these two SNPs
and performed a meta-analysis among European and Asian
populations.
RESULTS—The T-allele of GCKR rs780094 was associated with
increased triglycerides (P  5.4  10
7), while the A-allele of
GCK rs1799884 was associated with higher FPG (P  3.1 
10
7). A novel interaction effect between the two SNPs on FPG
was also observed (P  0.0025). Meta-analyses strongly sup-
ported the additive effects of the two SNPs on FPG and triglyc-
erides, respectively.
CONCLUSIONS—In support of the intimate relationship be-
tween glucose and lipid metabolisms, GCKR and GCK genetic
polymorphisms interact to increase FPG in healthy adults and
adolescents. These risk alleles may contribute to increased
diabetes risk in subjects who harbor other genetic or environ-
mental/lifestyle risk factors. Diabetes 58:765–769, 2009
T
he glycolytic enzyme glucokinase (GCK) is a
glucose sensor that plays a key role in maintain-
ing blood glucose homeostasis. In the pancreatic
-cells, GCK controls insulin secretion and bio-
synthesis (1). In the liver, GCK regulates glycogen synthe-
sis and gluconeogenesis, and its activity is competitively
inhibited by glucokinase regulatory protein (GCKR) (1,2).
In support of these functions, rare mutations in the GCK
gene have been found to be associated with maturity-onset
diabetes of the young (MODY), permanent neonatal dia-
betes, and hyperinsulinemia of infancy (3). Moreover, a
common promoter variant (30A) (rs1799884) of GCK has
been found to be associated with increased fasting plasma
glucose (FPG) and lowered birth weight in general Cau-
casian populations (4,5). Recently, a genome-wide associ-
ation (GWA) study conducted by the Diabetes Genetics
Initiative identiﬁed a common intronic polymorphism at
GCKR (rs780094) associated with plasma triglyceride level
(6). Subsequent independent studies in Danish (7) and
French (8) populations, as well as meta-analysis and ﬁne-
mapping (9) studies, conﬁrmed that the minor alleles of
rs780094 and rs1260326 (Pro446Leu), which are in strong
linkage disequilibrium (LD), were associated with higher
levels of triglyceride and C-reactive protein but lower
fasting glucose, insulin, and/or insulin resistance.
In this study, we examined the association of the GCKR
rs780094 and GCK rs1799884 polymorphisms with type 2
diabetes–related quantitative traits in two independent
samples of 600 adult and 986 adolescent Chinese residents
in Hong Kong. Due to the intimate relationship between
glucose and lipid metabolisms (10) and the functional
interaction between GCKR and GCK, we also hypothe-
sized the presence of epistasis effects between these two
single nucleotide polymorphisms (SNPs) on FPG and
fasting triglyceride levels.
We genotyped two SNPs, rs1799884 in GCK and
rs780094 in GCKR, in a total of 1,586 healthy subjects
including adults and adolescents. The frequencies of the
A-allele of rs1799884 were similar between our adult (0.16)
and adolescent (0.19) cohorts, as well as the HapMap CHB
data (0.20). Although the T-allele frequencies of rs780094
in our data (0.46 for both cohorts) were lower than in the
HapMap CHB (0.60), they were similar to the frequency
reported in a group of Singapore Chinese (0.46) from a
meta-analysis study (9).
The clinical characteristics of the adult and adolescent
cohorts are summarized in Table 1. When comparing the
From the
1Department of Medicine and Therapeutics, Chinese University of
Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China;
2Roche
Pharmaceuticals, Nutley, New Jersey; the
3Li Ka Shing Institute of Health
Sciences, Chinese University of Hong Kong, Prince of Wales Hospital,
Shatin, Hong Kong, China; the
4Hong Kong Institute of Diabetes and
Obesity, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin,
Hong Kong, China.
Corresponding author: Juliana C.N. Chan, jchan@cuhk.edu.hk.
Received 16 September 2008 and accepted 5 December 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 10 Decem-
ber 2008. DOI: 10.2337/db08-1277.
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
BRIEF REPORT
DIABETES, VOL. 58, MARCH 2009 765distributions of metabolic traits among different genotype
carriers of GCKR rs780094, we observed consistent and
strong association of the minor T-allele with increased
triglycerides in both adult and adolescent cohorts (4.0 
10
6  P  0.005), after adjusting for age, sex, and BMI
(Table 2). We also observed a strong association of the
minor A-allele of GCK rs1799884 with increased FPG in
both cohorts (P  6.4  10
5) after adjusting for covari-
ates (Table 3). The associations became more signiﬁcant
in the combined cohort (P  5.4  10
7 for triglycerides
with rs780094; P  3.1  10
7 for FPG with rs1799884)
(Tables 2 and 3) and remained signiﬁcant after controlling
for false discovery rate (P  0.0056 for triglycerides with
rs780094; P  0.0028 for FPG with rs1799884). These
ﬁndings are in agreement with reports from Caucasian
populations (4,6–9,11–13), as well as a recent Japanese
study (mean triglyceride levels of 1.07, 1.13, and 1.18
mmol/l, respectively, for CC, CT, and TT genotypes of
rs780094, P  0.097) (14).
We further examined possible gene-gene interaction
effects of GCKR rs780094 and GCK rs1799884 on fasting
triglycerides and FPG in the combined cohort using addi-
tive genetic models (Fig. 1A). There was a highly signiﬁ-
cant interaction effect between the two SNPs on FPG (P 
0.0025 for the interaction after adjusting for age, sex, BMI,
and study cohort). Each copy of the rs1799884 A-allele was
associated with a 0.18 (P  0.0001), 0.09 (P  0.0002), and
0.02 mmol/l (P  0.53) change in FPG levels for rs780094
TT, CT, and CC carriers, respectively. On the other hand,
the T-allele of rs780094 showed a trend of increased FPG
in rs1799884 AA carriers (0.14 mmol/l per allele, P  0.13)
but decreased FPG (0.05 mmol/l per allele) in GG
carriers (P  0.0045). However, no interaction was ob-
served for fasting triglycerides (Fig. 1B).
Several studies have reported the reciprocal effect of the
C-allele of rs7800094 with decreased triglycerides but
increased FPG, as well as the joint additive effects of
rs7800094 and rs1799884 on FPG levels (7–9). However,
only a Danish study examined nonadditive epistasis ef-
fects, and no interaction between these two SNPs was
found (8). Our results suggest a more complex scenario.
The risk effect of the A-allele of GCK rs1799884 on FPG
was strongest in TT carriers of rs780094, followed by CT
and CC carriers. Similar to other studies, we observed that
the C-allele of rs780094 was associated with increased
TABLE 1
Clinical and metabolic characteristics of 1,586 healthy Chinese
adults and adolescents
Adults Adolescents
n (male/female) 600 (270/330) 986 (463/523)
Age (years) 41.4  10.5 15.3  1.9
BMI (kg/m
2) 22.9  3.3 19.9  3.5
Systolic blood pressure
(mmHg) 115.4  16.3 118.0  12.5
Diastolic blood pressure
(mmHg) 72.3  11.2 72.6  9.6
Total cholesterol (mmol/l) 5.0  0.9 4.2  0.7
Triglycerides (mmol/l) 0.9 (0.6–1.3) 0.8 (0.6–1.0)
HDL cholesterol (mmol/l) 1.6  0.4 1.6  0.3
LDL cholesterol (mmol/l) 3.0  0.8 2.3  0.6
FPG (mmol/l) 4.8  0.4 4.7  0.3
Fasting plasma insulin
(pmol/l) 41.2 (26.5–58.7) 45.1 (35.3–60.4)
Data are means  SD or median (interquartile range).
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766 DIABETES, VOL. 58, MARCH 2009FPG, but only in carriers of the more common GG variant
of rs1799884 (P  0.0045), whereas a nominal association
in the opposite direction was observed for AA carriers
(P  0.13). This interaction explains the lack of overall
association of rs7800094 with FPG and fasting insulin
levels in our population.
The interaction effect is possibly due to the perturbation
of the upstream GCKR/GCK system, in which failure of the
receptor (GCKR) may inﬂuence the ability of GCK poly-
morphisms to confer effect on FPG levels. Despite smaller
sample sizes in separate cohorts, these interaction effects
showed a nominal signiﬁcance in both adult (P  0.058)
and adolescent (P  0.022) cohorts, suggesting that our
ﬁnding is unlikely to be due to chance alone (supplemen-
tary Fig. 1A and B, available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db08-
1277/DC1). Due to the rarity of the rs1799884 AA genotype
in both Europeans and Asians (4 and 3%, respectively), as
well as the lower TT genotype frequency of rs7800094 in
Europeans versus Asians (14 vs. 23%, respectively) (7), the
lack of interaction seen in Europeans may be partly due to
the rarity of the AA/TT high-risk carriers and the corre-
sponding low power of detection. Alternatively, different
risk-conferring alleles for the same gene are now increas-
ingly recognized, which may confound the association
(15,16). Additional interaction analyses in other studies
are warranted to clarify our ﬁndings.
Meta-analysis of the association between GCKR
(rs780094) and fasting triglycerides in combined European
and Asian cohorts showed increases of 0.10 (95% CI
0.07–0.13) and 0.22 (0.18–0.26) in standardized mean
difference (SMD) for the CT and TT genotypes, respec-
tively, when compared with the CC reference genotype
(supplementary Fig. 2). Likewise, an additive trend of
increases of 0.14 (0.10–0.18) and 0.31 (0.12–0.49) in SMD
of FPG for AG and AA genotypes, respectively, when
compared with the GG reference genotype, was observed
for GCK (rs1799884) (supplementary Fig. 3). Due to sig-
niﬁcant heterogeneity among the study cohorts (P  0.1),
the combined SMDs were calculated based on a random-
effects model.
Our meta-analyses of the association between GCKR
and triglycerides and between GCK and FPG, using com-
bined European and Asian data, strongly support the
additive effects of the risk alleles of the two SNPs on
triglycerides and FPG. Nevertheless, there are notable
differences in the effect size between the European and
Asian studies. Given interethnic differences in risk-allele
frequency, genetic effect size, and environmental expo-
sure, one might expect considerable variation in the
population-attributable risk of these genotypes on diabe-
tes in different populations.
In conclusion, we have conﬁrmed the risk associations
of two common genetic polymorphisms of GCK and GCKR
on type 2 diabetes–related metabolic traits as well as the
signiﬁcant interactive effects of these polymorphisms on
FPG in healthy Chinese adults and adolescents. These risk
alleles may add to the overall risk of type 2 diabetes in
subjects who harbor other genetic or environmental/life-
style factors. Finally, the interactions of these two genetic
polymorphisms have provided a hypothesis to improve our
understanding of dysregulation of intermediary metabo-
lism. This hypothesis, that polymorphisms at GCKR may
perturb the GCKR/GCK system and thus modify the effect
of GCK polymorphisms and lead to altered glucose metab-
olism, warrants further functional studies.
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The study design, ascertainment, inclusion criteria, and phenotyping of the
study subjects have been described previously (15,17,18). All subjects were of
southern Han Chinese ancestry and residing in Hong Kong. The adult cohort
(mean age 41.4  10.5 years, 45% male) consists of 600 participants of a
community-based health screening program or hospital staff. The adolescent
cohort consists of 986 healthy subjects (mean age 15.3  1.9 years, 47% male)
recruited from a population-based school survey for risk factor assessment.
Subjects with FPG 6.1 mmol/l were excluded. This study was approved by
the Clinical Research Ethics Committee of the Chinese University of Hong
Kong. Written informed consent was obtained from all participants or parents
of adolescents as appropriate.
All study subjects were examined in the morning after an overnight fast.
Anthropometric parameters including body weight, height, and blood pressure
were measured. Fasting blood samples were collected for measurement of
FPG, insulin, and lipids. FPG, total cholesterol, triglycerides, and HDL
cholesterol were measured enzymatically by the Roche Modular Analytics
system (Roche Diagnostics, Mannheim, Germany) with precision of the assays
within that speciﬁed by the manufacturer. Plasma insulin was measured by an
enzyme-linked immunosorbent assay (DAKOCytomation, Cambridgeshire,
U.K.).
Genotyping. Based on the existing evidence of association of GCKR rs780094
and GCK rs1799884 polymorphisms with triglycerides, FPG, and type 2
diabetes (4,5,7–9,11,12,14), these two SNPs were genotyped in all study
subjects using genomic DNA. We did not attempt to test for association of all
tagging SNPs of the respective genes. The GCKR rs1260326 polymorphism
was also genotyped in the 600-adult cohort in order to assess its LD with
rs780094. Due to their strong LD (r
2  0.9 in both HapMap CEU data and the
present Chinese study), subsequent analyses were performed for rs780094
only. Genotyping was performed at the McGill University and Genome Quebec
Innovation Centre using primer extension of multiplex products with detec-
tion by MALDI-TOF mass spectroscopy on a Sequenom MassARRAY platform
(Sequenom, San Diego, CA). Both SNPs were in Hardy-Weinberg equilibrium
(P  0.05) in adult and adolescent cohorts separately, as assessed by the exact
test of PLINK (19). The genotype call rates were 92% for both SNPs.
Genotyping accuracy was demonstrated by a 100% concordance rate in 26
blinded duplicate samples.
Statistical analysis. Continuous data are presented as mean  SD or median
(interquartile range). Plasma triglycerides and fasting plasma insulin were
logarithmically transformed due to skewed distributions. Each trait was
Winsorized separately in adult and adolescent cohorts by replacing extreme
values with four SDs from the mean (20,21). Less than 0.3% of data were
replaced.
Within each cohort, associations between genotypes and metabolic traits
were tested by multiple linear regression, with age, sex, and BMI as covariates
(where appropriate). In the combined analysis, an additional dummy variable
“study cohort” coded as 0 for adults and 1 for adolescents was included in the
regression model. To assess gene-gene interaction effect on FPG and triglyc-
eride levels, linear regression including the main and interaction effects of
GCKR rs780094 and GCK rs1799884 under additive models was applied.
Multiple testing of phenotypic traits and SNPs was corrected by controlling
the false discovery rate using the Benjamini-Hochberg approach (22,23).
Meta-analyses of the associations of GCKR rs780094 with triglycerides and
GCK rs1799884 with FPG were assessed by MedCalc for Windows, version
9.2.0.0 (MedCalc Software, Mariakerke, Belgium). For the association of
GCKR rs780094 on triglyceride, the T-allele of rs1260326 in the French study
(8) was used as proxy for the T-allele of rs780094 (r
2  0.9 in the HapMap CEU
data). Hedges G statistic was used to calculate the SMD (the difference
between the two means divided by the pooled standard deviation) across
studies under the ﬁxed effects model. To address heterogeneity of SMDs
across studies (Cochran’s Q statistic, P  0.1), the overall effect size (SMD)
under the random-effects model, in which both random variations within and
between different studies were incorporated (24), was reported.
We estimated study power using a genetic power calculator (25). Assuming
an additive model with the observed frequencies of 0.46 for the T-allele of
GCKR rs780094 and 0.17 for the A-allele of GCK rs1799884 in our Chinese
population, our sample size has 87% power to detect a per-allele effect of
increasing triglycerides by 0.16 mmol/l for rs780094 (7) and 70% power of
increasing FPG by 0.1 mmol/l for rs1799884 (12), at an  level of 0.05. All
statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary,
NC) unless speciﬁed otherwise. Two-tailed P values 0.05 were considered
statistically signiﬁcant.
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